Logo image of BHC

BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis

NYSE:BHC - New York Stock Exchange, Inc. - CA0717341071 - Common Stock - Currency: USD

5.774  +0.01 (+0.24%)

Fundamental Rating

4

Overall BHC gets a fundamental rating of 4 out of 10. We evaluated BHC against 193 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

BHC had positive earnings in the past year.
BHC had a positive operating cash flow in the past year.
In the past 5 years BHC always reported negative net income.
Of the past 5 years BHC 4 years had a positive operating cash flow.
BHC Yearly Net Income VS EBIT VS OCF VS FCFBHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B -4B

1.2 Ratios

The Return On Assets of BHC (-0.15%) is better than 80.83% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.60%, BHC belongs to the top of the industry, outperforming 84.46% of the companies in the same industry.
BHC had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 14.96%.
The last Return On Invested Capital (6.60%) for BHC is above the 3 year average (5.98%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.15%
ROE N/A
ROIC 6.6%
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
BHC Yearly ROA, ROE, ROICBHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

With an excellent Operating Margin value of 19.03%, BHC belongs to the best of the industry, outperforming 86.53% of the companies in the same industry.
In the last couple of years the Operating Margin of BHC has grown nicely.
BHC has a Gross Margin of 70.78%. This is in the better half of the industry: BHC outperforms 78.24% of its industry peers.
BHC's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.03%
PM (TTM) N/A
GM 70.78%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
BHC Yearly Profit, Operating, Gross MarginsBHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BHC is destroying value.
Compared to 1 year ago, BHC has more shares outstanding
Compared to 5 years ago, BHC has more shares outstanding
The debt/assets ratio for BHC has been reduced compared to a year ago.
BHC Yearly Shares OutstandingBHC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
BHC Yearly Total Debt VS Total AssetsBHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.2 Solvency

Based on the Altman-Z score of 0.19, we must say that BHC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BHC (0.19) is comparable to the rest of the industry.
BHC has a debt to FCF ratio of 17.69. This is a negative value and a sign of low solvency as BHC would need 17.69 years to pay back of all of its debts.
BHC has a Debt to FCF ratio of 17.69. This is in the better half of the industry: BHC outperforms 78.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 17.69
Altman-Z 0.19
ROIC/WACC0.97
WACC6.8%
BHC Yearly LT Debt VS Equity VS FCFBHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.35 indicates that BHC should not have too much problems paying its short term obligations.
BHC's Current ratio of 1.35 is on the low side compared to the rest of the industry. BHC is outperformed by 73.58% of its industry peers.
BHC has a Quick Ratio of 1.35. This is a bad value and indicates that BHC is not financially healthy enough and could expect problems in meeting its short term obligations.
BHC has a worse Quick ratio (0.97) than 76.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 0.97
BHC Yearly Current Assets VS Current LiabilitesBHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

3

3. Growth

3.1 Past

BHC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.55%.
The Earnings Per Share has been decreasing by -2.91% on average over the past years.
The Revenue has grown by 9.91% in the past year. This is quite good.
Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 2.28% on average per year.
EPS 1Y (TTM)3.55%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.25%
Revenue 1Y (TTM)9.91%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%5.29%

3.2 Future

Based on estimates for the next years, BHC will show a small growth in Earnings Per Share. The EPS will grow by 1.24% on average per year.
The Revenue is expected to decrease by -0.38% on average over the next years.
EPS Next Y20.4%
EPS Next 2Y11.09%
EPS Next 3Y15.37%
EPS Next 5Y1.24%
Revenue Next Year4.86%
Revenue Next 2Y4.28%
Revenue Next 3Y3.25%
Revenue Next 5Y-0.38%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BHC Yearly Revenue VS EstimatesBHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
BHC Yearly EPS VS EstimatesBHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

BHC is valuated cheaply with a Price/Earnings ratio of 1.52.
98.45% of the companies in the same industry are more expensive than BHC, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.99. BHC is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 1.24 indicates a rather cheap valuation of BHC.
Based on the Price/Forward Earnings ratio, BHC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
BHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 1.52
Fwd PE 1.24
BHC Price Earnings VS Forward Price EarningsBHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaper than 90.67% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1.75
EV/EBITDA 7.25
BHC Per share dataBHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BHC's earnings are expected to grow with 15.37% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y11.09%
EPS Next 3Y15.37%

More info and screens

0

5. Dividend

5.1 Amount

BHC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAUSCH HEALTH COS INC

NYSE:BHC (8/7/2025, 3:30:54 PM)

5.774

+0.01 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners58.71%
Inst Owner Change0.01%
Ins Owners11.02%
Ins Owner Change16.41%
Market Cap2.13B
Analysts48.89
Price Target7.47 (29.37%)
Short Float %2.3%
Short Ratio3.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.74%
Min EPS beat(2)-25.13%
Max EPS beat(2)-4.34%
EPS beat(4)2
Avg EPS beat(4)-5.77%
Min EPS beat(4)-25.13%
Max EPS beat(4)5.95%
EPS beat(8)5
Avg EPS beat(8)-0.95%
EPS beat(12)6
Avg EPS beat(12)-6.23%
EPS beat(16)8
Avg EPS beat(16)-5.16%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)0.39%
Revenue beat(4)3
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.66%
Revenue beat(8)6
Avg Revenue beat(8)1.53%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.24%
PT rev (3m)18.6%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)22.18%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.6%
Revenue NQ rev (3m)9.85%
Revenue NY rev (1m)1.75%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 1.52
Fwd PE 1.24
P/S 0.22
P/FCF 1.75
P/OCF 1.34
P/B N/A
P/tB N/A
EV/EBITDA 7.25
EPS(TTM)3.79
EY65.64%
EPS(NY)4.65
Fwd EY80.58%
FCF(TTM)3.29
FCFY56.99%
OCF(TTM)4.32
OCFY74.84%
SpS26.33
BVpS-3.2
TBVpS-47.71
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.15%
ROE N/A
ROCE 8.36%
ROIC 6.6%
ROICexc 6.96%
ROICexgc 31.94%
OM 19.03%
PM (TTM) N/A
GM 70.78%
FCFM 12.5%
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
ROICexc(3y)6.26%
ROICexc(5y)5.63%
ROICexgc(3y)44%
ROICexgc(5y)37.54%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexcg growth 3Y34.27%
ROICexcg growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 17.69
Debt/EBITDA 6.84
Cap/Depr 30.43%
Cap/Sales 3.92%
Interest Coverage 250
Cash Conversion 51.45%
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 0.97
Altman-Z 0.19
F-Score5
WACC6.8%
ROIC/WACC0.97
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.55%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.25%
EPS Next Y20.4%
EPS Next 2Y11.09%
EPS Next 3Y15.37%
EPS Next 5Y1.24%
Revenue 1Y (TTM)9.91%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%5.29%
Revenue Next Year4.86%
Revenue Next 2Y4.28%
Revenue Next 3Y3.25%
Revenue Next 5Y-0.38%
EBIT growth 1Y10.77%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year13.62%
EBIT Next 3Y9.06%
EBIT Next 5Y-0.57%
FCF growth 1Y257.31%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y412.52%
OCF growth 3Y3.85%
OCF growth 5Y1.25%